Global Psoriasis Biosimilars Market Report 2025

Item added to cart!

Published : December 2025

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Psoriasis Biosimilars Global Market Report 2025

Name: Psoriasis Biosimilars Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Class (TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars), By Disease Type (Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis), By Route Of Administration (Subcutaneous, Intravenous, Oral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Psoriasis Biosimilars Market Overview

• Psoriasis Biosimilars market size has reached to $7.32 billion in 2024

• Expected to grow to $12.43 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%

• Growth Driver: Rising Psoriatic Arthritis Diagnoses Fueling The Growth Of The Market Due To Increasing Early Detection And Cost-Effective Treatment Demand

• Market Trend: Launch Of First Ustekinumab Biosimilar Autoinjector Enhances Plaque Psoriasis Treatment Options

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Psoriasis Biosimilars Market?

Psoriasis biosimilars are biologic medications designed to closely mimic the structure, function, safety, and effectiveness of already approved reference biologics used in the treatment of moderate to severe psoriasis. These biosimilars provide a cost-effective alternative to original biologics, helping to improve patient access to advanced therapies without compromising clinical performance or quality.

The main types of drug classes in psoriasis biosimilars are TNF-Alpha Inhibitors, infliximab, etanercept, adalimumab, and other biosimilars. TNF-alpha inhibitors are a class of biologic drugs that block tumor necrosis factor-alpha (TNF-a), a protein responsible for inflammation in psoriasis. It is used for various disease types, such as plaque psoriasis, guttate psoriasis, inverse psoriasis, and pustular psoriasis, and administered through subcutaneous, intravenous, oral, and topical routes. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Psoriasis Biosimilars Market Size and growth rate 2025 to 2029: Graph

What Is The Psoriasis Biosimilars Market Size 2025 And Growth Rate?

What Is The Psoriasis Biosimilars Market Growth Forecast?

The psoriasis biosimilars market size is expected to see rapid growth in the next few years. It will grow to $12.43 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing psoriasis incidence worldwide, switching policies and interchangeability laws, growth of biosimilar manufacturing, improved patient and physician education, and bundled pricing and value-based contracts. Major trends in the forecast period include innovative biosimilar manufacturing platforms, AI-driven patient stratification, the introduction of advanced drug delivery devices, the development of next-generation formulations, and strategic industry partnerships.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Psoriasis Biosimilars Market Segmented?

1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars

2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis

3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars

2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars

3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars

4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars

5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars

What Is Driving The Psoriasis Biosimilars Market? Rising Psoriatic Arthritis Diagnoses Fueling The Growth Of The Market Due To Increasing Early Detection And Cost-Effective Treatment Demand

The rising psoriatic arthritis diagnosis rates are expected to propel the growth of the psoriasis biosimilars market going forward. Psoriatic arthritis refers to a chronic autoimmune condition that causes inflammation in the joints and skin, often affecting individuals with a history of psoriasis. The psoriatic arthritis diagnosis rates are increasing, particularly due to improved screening protocols among individuals with psoriasis, which enable earlier detection and more accurate diagnosis by identifying subtle joint symptoms that might have previously gone unnoticed. Psoriasis biosimilars help manage psoriatic arthritis by providing affordable alternatives to biologic therapies, effectively reducing joint inflammation and skin symptoms. For instance, in May 2024, according to the National Institutes of Health (NIH), a US-based government agency, in 2022, psoriatic arthritis (PsA) had a prevalence of 0.221% and an incidence rate of 13.54 per 100,000 people. Therefore, the rising psoriatic arthritis diagnosis rates are driving the growth of the psoriasis biosimilars industry.

Who Are The Major Players In The Global Psoriasis Biosimilars Market?

Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Merck & Co. Inc., Amgen Inc., Biogen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Samsung Bioepis Co. Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Torrent Pharmaceuticals Ltd., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Reliance Life Sciences Pvt. Ltd., and Alvotech hf.

What Are The Key Trends Of The Global Psoriasis Biosimilars Market? Launch Of First Ustekinumab Biosimilar Autoinjector Enhances Plaque Psoriasis Treatment Options

Major companies operating in the psoriasis biosimilars market are focusing on introducing innovative solutions, such as biosimilars for plaque psoriasis, to enhance treatment accessibility, reduce healthcare costs, and improve patient outcomes. Biosimilars for plaque psoriasis are lower-cost, highly similar alternatives to approved biologic drugs used to treat the chronic autoimmune skin condition characterized by red, scaly patches. For instance, in May 2025, Sandoz Group AG, a Switzerland-based company that focuses on generic pharmaceuticals and biosimilars, launched the Pyzchiva autoinjector, the first commercially available ustekinumab biosimilar autoinjector. Pyzchiva is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, and Crohn's disease, as well as pediatric patients aged six years and older (weighing over 60 kg) with plaque psoriasis. Designed to enhance patient adherence and quality of life, the autoinjector features accurate automatic dosing, reduced injection pain, a compact design, and flexible storage options for more comfortable self-administration.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Psoriasis Biosimilars Market? Sandoz Partnered With Samsung Bioepis To Commercialize SB17 Ustekinumab Biosimilar In Europe And North America

In September 2023, Sandoz Group AG, a Switzerland-based pharmaceutical company, partnered with Samsung Bioepis to commercialize the biosimilar SB17 (ustekinumab). This collaboration leverages the strengths of both companies to bring the ustekinumab biosimilar, used to treat conditions such as plaque psoriasis, to markets in Europe and North America. The partnership aims to expand patient access to high-quality, cost-effective immunology treatments while reinforcing Sandoz’s leadership in the global biosimilars market. Samsung Bioepis is a South Korea-based biopharmaceutical company focused on developing and commercializing biosimilar drugs, including those used to treat plaque psoriasis.

What Is The Regional Outlook For The Global Psoriasis Biosimilars Market?

North America was the largest region in the psoriasis biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Psoriasis Biosimilars Market?

The psoriasis biosimilars market consists of sales of tumor necrosis factor inhibitors, monoclonal antibodies, subcutaneous and intravenous formulations, subcutaneous injections, and interleukin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Psoriasis Biosimilars Industry?

The psoriasis biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the psoriasis biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Psoriasis Biosimilars Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$8.16 billion
Revenue Forecast In 2034	$12.43 billion
Growth Rate	CAGR of 11.1% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	Drug Class, Disease Type, Route Of Administration, Distribution Channel
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Merck & Co. Inc., Amgen Inc., Biogen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Samsung Bioepis Co. Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Torrent Pharmaceuticals Ltd., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Reliance Life Sciences Pvt. Ltd., and Alvotech hf.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Psoriasis Biosimilars Market Characteristics

3. Psoriasis Biosimilars Market Trends And Strategies

4. Psoriasis Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Psoriasis Biosimilars Growth Analysis And Strategic Analysis Framework

5.1. Global Psoriasis Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Psoriasis Biosimilars Market Growth Rate Analysis

5.4. Global Psoriasis Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Psoriasis Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Psoriasis Biosimilars Total Addressable Market (TAM)

6. Psoriasis Biosimilars Market Segmentation

6.1. Global Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

TNF-Alpha Inhibitors

Infliximab

Etanercept

Adalimumab

Other Biosimilars

6.2. Global Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Plaque Psoriasis

Guttate Psoriasis

Inverse Psoriasis

Pustular Psoriasis

6.3. Global Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Subcutaneous

Intravenous

Oral

Topical

6.4. Global Psoriasis Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.5. Global Psoriasis Biosimilars Market, Sub-Segmentation Of TNF-Alpha Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monoclonal Antibody Biosimilars

Fusion Protein Biosimilars

6.6. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Remicade Biosimilars

CT-P13 Biosimilars

6.7. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Etanercept, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Enbrel Biosimilars

SB4 Biosimilars

6.8. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Adalimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Humira Biosimilars

ABP 501 Biosimilars

6.9. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Other Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ustekinumab Biosimilars

Secukinumab Biosimilars

7. Psoriasis Biosimilars Market Regional And Country Analysis

7.1. Global Psoriasis Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Psoriasis Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Psoriasis Biosimilars Market

8.1. Asia-Pacific Psoriasis Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Psoriasis Biosimilars Market

9.1. China Psoriasis Biosimilars Market Overview

9.2. China Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Psoriasis Biosimilars Market

10.1. India Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Psoriasis Biosimilars Market

11.1. Japan Psoriasis Biosimilars Market Overview

11.2. Japan Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Psoriasis Biosimilars Market

12.1. Australia Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Psoriasis Biosimilars Market

13.1. Indonesia Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Psoriasis Biosimilars Market

14.1. South Korea Psoriasis Biosimilars Market Overview

14.2. South Korea Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Psoriasis Biosimilars Market

15.1. Western Europe Psoriasis Biosimilars Market Overview

15.2. Western Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Psoriasis Biosimilars Market

16.1. UK Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Psoriasis Biosimilars Market

17.1. Germany Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Psoriasis Biosimilars Market

18.1. France Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Psoriasis Biosimilars Market

19.1. Italy Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Psoriasis Biosimilars Market

20.1. Spain Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Psoriasis Biosimilars Market

21.1. Eastern Europe Psoriasis Biosimilars Market Overview

21.2. Eastern Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Psoriasis Biosimilars Market

22.1. Russia Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Psoriasis Biosimilars Market

23.1. North America Psoriasis Biosimilars Market Overview

23.2. North America Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Psoriasis Biosimilars Market

24.1. USA Psoriasis Biosimilars Market Overview

24.2. USA Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Psoriasis Biosimilars Market

25.1. Canada Psoriasis Biosimilars Market Overview

25.2. Canada Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Psoriasis Biosimilars Market

26.1. South America Psoriasis Biosimilars Market Overview

26.2. South America Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Psoriasis Biosimilars Market

27.1. Brazil Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Psoriasis Biosimilars Market

28.1. Middle East Psoriasis Biosimilars Market Overview

28.2. Middle East Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Psoriasis Biosimilars Market

29.1. Africa Psoriasis Biosimilars Market Overview

29.2. Africa Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Psoriasis Biosimilars Market Competitive Landscape And Company Profiles

30.1. Psoriasis Biosimilars Market Competitive Landscape

30.2. Psoriasis Biosimilars Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis

31. Psoriasis Biosimilars Market Other Major And Innovative Companies

31.1. Fresenius Kabi AG

31.2. Intas Pharmaceuticals Ltd.

31.3. STADA Arzneimittel AG

31.4. Aurobindo Pharma Ltd.

31.5. Dr. Reddy’s Laboratories Ltd.

31.6. Cipla Ltd.

31.7. Samsung Bioepis Co. Ltd.

31.8. Lupin Ltd.

31.9. Zydus Lifesciences Ltd.

31.10. Celltrion Inc.

31.11. Torrent Pharmaceuticals Ltd.

31.12. Bio-Thera Solutions Ltd.

31.13. Coherus BioSciences Inc.

31.14. mAbxience S.A.

31.15. Reliance Life Sciences Pvt. Ltd.

32. Global Psoriasis Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Psoriasis Biosimilars Market

34. Recent Developments In The Psoriasis Biosimilars Market

35. Psoriasis Biosimilars Market High Potential Countries, Segments and Strategies

35.1 Psoriasis Biosimilars Market In 2029 - Countries Offering Most New Opportunities

35.2 Psoriasis Biosimilars Market In 2029 - Segments Offering Most New Opportunities

35.3 Psoriasis Biosimilars Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Psoriasis Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Psoriasis Biosimilars Market, Sub-Segmentation Of TNF-Alpha Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Etanercept, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Adalimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Other Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Psoriasis Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Psoriasis Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Pfizer Inc. Financial Performance

Table 81: Merck & Co. Inc. Financial Performance

Table 82: Amgen Inc. Financial Performance

Table 83: Biogen Inc. Financial Performance

Table 84: Sandoz Group AG Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Psoriasis Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Psoriasis Biosimilars Market, Sub-Segmentation Of TNF-Alpha Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Etanercept, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Adalimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Psoriasis Biosimilars Market, Sub-Segmentation Of Other Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Psoriasis Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Psoriasis Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Pfizer Inc. Financial Performance

Figure 81: Merck & Co. Inc. Financial Performance

Figure 82: Amgen Inc. Financial Performance

Figure 83: Biogen Inc. Financial Performance

Figure 84: Sandoz Group AG Financial Performance

Global Complete Nutrition Products Market Landscape: Trends and Market Share to 2029

Competitive and Market Trend Analysis of Conjugate Vaccine Industry Through 2029

Industry Trends Show Cosmeceuticals Market Set to Expand at 8.8% CAGR Until 2029

Strategic Report on Cosmetic Ingredients Market: Growth Opportunities and Emerging Challenges

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Rail Road Construction Global Market Report 2025 – By Train Type (Metro, Light Rail, Bullet Train or High-Speed Rail (HSR) ), By Construction Type (New Construction, Renovation), By Application (Urban, Rural ) – Impact o...

Freight Railcar Parts Global Market Report 2025 – By Component (Gears, Wheels, Axles And Bearings, Side Frames, Draft Systems, Couplers And Yokes, Airbrakes, Other Components), By Type (Autocar, Box Car, Center Beam, Cov...

Cross Laminated Timber Global Market Report 2025 – By Type (Adhesive Bonded, Mechanically Fastened ), By Application (Residential, Institutional, Commercial, Other Applications ), By End User (Structural, Non-Structural ...

Passenger Rail Transport Global Market Report 2025 – By Type (Medium-Distance Passenger Transport, Long-Distance Passenger Transport, Short-Distance Passenger Transport), By Service Type (Transportation, Services Allied ...

Rail Road Construction Global Market Report 2025 – By Train Type (Metro, Light Rail, Bullet Train or High-Speed Rail (HSR) ), By Construction Type (New Construction, Renovation), By Application (Urban, Rural ) – Impact o...

Rail Asset Management Global Market Report 2025 – By Solution (Asset Performance Management, Analytics, Asset Planning & Scheduling, Security, Workforce Management, Other Solutions), By Services (Professional Services, M...

Finger Print Vehicle Access Global Market Report 2025 – By Type (Fingerprint Opens The Door, Fingerprint Ignition), By Vehicle (Passenger Car, Battery Electric Vehicle), By Application (Door, Steering Wheel, Car Mirror, ...

Frequently Asked Questions

What is the definition of the Psoriasis Biosimilars market?

How will the Psoriasis Biosimilars market drivers and restraints affect the market dynamics? What forces will shape the Psoriasis Biosimilars industry going forward?

The market major growth driver - Rising Psoriatic Arthritis Diagnoses Fueling The Growth Of The Market Due To Increasing Early Detection And Cost-Effective Treatment Demand. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Psoriasis Biosimilars market?

The psoriasis biosimilars market size has grown rapidly in recent years. It will grow from $7.32 billion in 2024 to $8.16 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to the rising cost burden of original biologics, the clinical success and safety data of early entrants, the expansion of indications beyond psoriasis, the growth in chronic disease prevalence, and hospital procurement policy reforms. The psoriasis biosimilars market size is expected to see rapid growth in the next few years. It will grow to $12.43 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing psoriasis incidence worldwide, switching policies and interchangeability laws, growth of biosimilar manufacturing, improved patient and physician education, and bundled pricing and value-based contracts. Major trends in the forecast period include innovative biosimilar manufacturing platforms, AI-driven patient stratification, the introduction of advanced drug delivery devices, the development of next-generation formulations, and strategic industry partnerships. For further insights on this market, request a sample here

How is the Psoriasis Biosimilars market segmented?

The psoriasis biosimilars market covered in this report is segmented
1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars
2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis
3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments:
1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars
2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars
3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars
4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars
5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars For further insights on this market, request a sample here

Which region has the largest share of the Psoriasis Biosimilars market? What are the other regions covered in the report?

North America was the largest region in the psoriasis biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Psoriasis Biosimilars market?

What are the key trends in the Psoriasis Biosimilars market?

Major trends in this market include Launch Of First Ustekinumab Biosimilar Autoinjector Enhances Plaque Psoriasis Treatment Options. For further insights on this market, request a sample here.